A Multicenter Study of NAP (AL-108) in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Schizophrenia
Interventions
DRUG

AL-108

AL-108, 5 mg/day- one spray in each nostril once per day

DRUG

AL-108

AL-108, 30 mg/day- 3 sprays in each nostril, twice per day

DRUG

Placebo

Placebo- 3 sprays in each nostril, twice per day

DRUG

Placebo

Placebo- one spray in each nostril, once per day

Trial Locations (8)

10032

Columbia University Medical Center, New York

10962

Nathan Kline Institute, Orangeburg

21228

Maryland Psychiatric Research Center, Catonsville

27710

Duke University Medical Center, Durham

63110

Washington University School of Medicine, St Louis

90073

UCLA, Los Angeles

02114

Massachusetts General Hospital, Boston

02215

Harvard Medical School, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Maryland

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Nathan Kline Institute for Psychiatric Research

OTHER

collaborator

Columbia University

OTHER

collaborator

Duke University

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

University of California, Los Angeles

OTHER